NOXOPHARM
Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company. The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy. At one level, Veyonda® enhances the cancer-killing effect of standard chemotherapy and radiotherapy, thereby enabling lower doses of these toxic therapies to be used.
NOXOPHARM
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2015-01-01
Address:
Turramurra, New South Wales, Australia
Country:
Australia
Website Url:
http://www.noxopharm.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
49 M AUD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Current Employees Featured
Founder
Stock Details
Investors List
The Lind Partners
The Lind Partners investment in Post-IPO Debt - Noxopharm
Official Site Inspections
http://www.noxopharm.com Semrush global rank: 4.51 M Semrush visits lastest month: 2.37 K
- Host name: a290d26420470737c.awsglobalaccelerator.com
- IP address: 15.197.133.181
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
